AbbVie Inc.'s stock rose 4% early Friday, after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025.

AbbVie (ABBV) stock gains as company sets 2025 earnings outlook in line with expectations after Q4 revenue beat and despite quarterly loss. Read more here.

AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid ...

With all the rapid advancements in technology and the race to be the next global disruptor through AI technology, Omar ...

AbbVie (ABBV) is expected to beat Q4 earnings estimates with strong performance from key products, including Skyrizi and ...